Skip to content

The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma

The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma: Clinical Trail

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06150144
Enrollment
40
Registered
2023-11-29
Start date
2023-05-25
Completion date
2025-05-25
Last updated
2024-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinoma, BCC

Keywords

Surgical excision, Basal cell carcinoma, clinical Trail, intralesional 5-fluorouracil

Brief summary

The investigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.

Detailed description

Brief Description: The investigatorswant to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months. Detailed Description: Clinicians routinely consider surgical removal as the best and sometimes the only cost-effective treatment of Basal cell carcinoma, but several studies have discussed other promising treatment approaches for BCC including 5% 5-FU cream which is indicated for the treatment of superficial BCC, in addition many studies have investigated the efficacy of the combination of 5-FU with Imiquimode or cryoablation presenting promising results, however when searching the medical literature there was only few studies dealing with types other than superficial BCC, in addition intralesional administration of 5-FU alone was not thoroughly assessed so far even though there are some studies showing positive results suggesting 5-FU to be a cost-effective alternative to surgical excision, but as these papers are asking for further studies and stronger evidence the invistigators decided to conduct this study in accordance with the best recommendations reached by latest medical literature.

Interventions

DRUG5-Fluorouracil

The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.

OTHERSURGERY

Total excision of the lesion

Sponsors

Aleppo University Hospital
CollaboratorUNKNOWN
University of Aleppo
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* 5 Years to 90 Years (Child, Adult, Older Adult). * Volunteer to participate in study * Superficial lesion * Nodular lesion (x ≤ 1.5 cm) patients are seen at the outpatient Department or in the dermatology wards at Aleppo University Hospital (AUH) over 12 months' period.

Exclusion criteria

* Ulcerative. * Nodular lesion (x ≥ 1.5 cm)

Design outcomes

Primary

MeasureTime frameDescription
Histologic complete response rate1 - 2 monthsdefined by absence of any tumor on the basis of histologic analysis of the excised specimen.

Secondary

MeasureTime frameDescription
Sides effect1 yearThe patient will be monitored and followed up for 365 days after the injection.

Countries

Syria

Contacts

Primary ContactIbrahim Arnaout, M.D. Candidate
ibrahim.arnaout25@gmail.com+963993279977
Backup ContactGeorge Zakhour, M.D. Candidate
geo.zakhour@yahoo.com+963 959 115 307

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026